The observed reduction of metastatic burden upon loss of stromal HSPG2 was not due to initial changes in cancer cell proliferation, as assessed by quantifying the in vivo luciferase signal and the in vitro doubling time of cancer cells co-cultured with CAFs (Supplementary Fig. 5d, e). Here, HSPG2 is linked to cancer.